Quick Takeaways:
- Merck Animal Health presented more than 50 studies at the 33rd World Buiatrics Congress, including seven oral presentations, 51 posters and a sponsored symposium covering neonatal calf health, respiratory disease, infectious diseases, parasitology and herd management.
- Research highlighted maternal vaccination against Cryptosporidium parvum, including GP40-mediated passive immunity, antibody transfer to calves and field outcomes related to calf health and therapeutic interventions. Additional studies examined respiratory disease prevention and responsible antibiotic use.
- The company also presented research on SenseHub Dairy monitoring technologies, exploring behavioral data for early disease detection, youngstock management, calf development and long-term performance, alongside studies evaluating intranasal bovine coronavirus vaccination and growth outcomes.
Why It Matters?
Merck Animal Health’s large data push at the World Buiatrics Congress—especially around maternal Cryptosporidium vaccination (GP40), intranasal bovine coronavirus vaccination and SenseHub behavior monitoring—reinforces its leadership in ruminant health and precision herd management, supporting premium, evidence‑based positioning against competitors. The Cryptosporidium and coronavirus vaccine data (showing reduced diarrhea duration and improved calf weight gain) can drive uptake in neonatal and respiratory disease prevention, while SenseHub’s whole‑life monitoring strengthens Merck’s digital‑health franchise in a livestock sensor market.
Source: Merck Animal Health
